课题基金 / 基金详情

HDL function and mortality in end stage renal disease

HDL function and mortality in end stage renal disease
终末期肾病的 HDL 功能和死亡率
批准号:
10205993
负责人:
Hamid Moradi
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-01-01 至 2022-12-31
关键词:
AcidsAgeAnti-Inflammatory AgentsAntioxidantsApolipoprotein A-IAreaAtherosclerosisAwardCaliforniaCardiovascular DiseasesCardiovascular systemCaringCell Culture TechniquesCeramidesCessation of lifeChronic Kidney FailureClinicalClinical DataClinical ResearchCoronary ArteriosclerosisData CollectionDeficiency DiseasesDiabetes MellitusDialysis patientsDialysis procedureDisease susceptibilityEnd stage renal failureEndocannabinoidsEnvironmentEthnic OriginEvaluationFatty AcidsFoundationsFunctional disorderFutureGenderGeneral PopulationGoalsHealthcare SystemsHemodialysisHigh Density Lipoprotein CholesterolHigh Density LipoproteinsHigh PrevalenceHypertensionIn VitroInflammationInvestigationK-Series Research Career ProgramsKnowledgeLaboratoriesLegal patentLipidsLow Density Lipoprotein oxidationMaintenanceMalignant NeoplasmsMeasurementMeasuresMediator of activation proteinMentorsMentorshipMetabolismModelingNational Institute of Diabetes and Digestive and Kidney DiseasesOutcomeOxidative StressPathway interactionsPatientsPharmacologyPharmacology StudyPhenotypePlayPopulationPrevalencePreventionProductionPropertyProspective cohortPublic HealthRaceResearch PersonnelResourcesRoleSamplingSerumSignal PathwayTechniquesTherapeuticTimeTrainingTraining ProgramsTranslational ResearchUnited StatesVeteransadjudicationamidaseatherogenesisbasecardiovascular disorder riskcardiovascular risk factorcareercohortdesignepidemiology studyexperienceexperimental studyhigh riskimprovedinhibitor/antagonistinnovationmilitary veteranmortalitymortality riskmultidisciplinarynew therapeutic targetnovelpatient populationprognosticprospectivepublic health relevancereverse cholesterol transporttargeted treatmenttool

项目摘要

项目成果

Hamid Moradi的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 大约9%的美国人口患有慢性肾脏疾病,尽管退伍军人中的患病率甚至更高,因为该患者人群中糖尿病和高血压(CKD的根本原因)的患病率很高。在这个惊人的数字中,大约有45万名患者患有终末期肾病(ESRD),需要维持透析。预计到2020年,ESRD患者人数将增加到70万人。透析患者的五年生存率约为35%,比许多癌症更差。这些死亡中有一半归因于心血管疾病(CVD)。因此,旨在发现可以识别CVD高风险患者的新途径/分子的研究至关重要。此外,可以探索这些途径以确定潜在的治疗靶点。鉴于HDL在预防和逆转CVD中的关键作用,旨在评估和改善ESRD患者HDL功能的研究具有相当大的临床和治疗价值。
英文摘要
DESCRIPTION (provided by applicant): Approximately 9% of the United States population have chronic kidney disease, although, this prevalence is even higher in Veterans given the high prevalence of diabetes and hypertension (underlying causes of CKD) in this patient population. Out of this staggering number, approximately 450,000 patients have end stage renal disease (ESRD) requiring maintenance dialysis. The number of patients with ESRD is expected to increase to 700,000 by 2020. Five year survival for patients on dialysis is about 35%, a rate worse than many cancers. Half of these deaths are attributed to cardiovascular disease (CVD). Therefore, investigations aimed at discovering novel pathways/molecules that can identify patients at high risk for CVD are of vital importance. Furthermore, these pathways can be explored to identify potential targets for therapy. Given the critical role HDL plays in prevention and reversal of CVD, studies aimed at evaluating and improving HDL function in ESRD patients are of considerable clinical and therapeutic value.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
Serum high density lipoprotein cholesterol level and risk of death: let's avoid the extremes.
血清高密度脂蛋白胆固醇水平和死亡风险:让我们避免极端情况。
DOI: 10.21037/jtd.2017.10.155
发表时间: 2017
期刊: Journal of thoracic disease
影响因子: 2.5
作者: [Moradi,Hamid, Streja,Elani, Kalantar-Zadeh,Kamyar]
通讯作者: Kalantar-Zadeh,Kamyar
DOI: 10.1016/s2213-8587(18)30304-8
发表时间: 2018-12
期刊: The lancet. Diabetes & endocrinology
影响因子: --
作者: [Yongen Chang;H. Moradi;K. Kalantar-Zadeh]
通讯作者: Yongen Chang;H. Moradi;K. Kalantar-Zadeh
DOI: 10.1016/j.jamda.2015.07.014
发表时间: 2015-11-01
期刊: Journal of the American Medical Directors Association
影响因子: 7.6
作者: [Ahmadi SF, Streja E, Zahmatkesh G, Streja D, Kashyap M, Moradi H, Molnar MZ, Reddy U, Amin AN, Kovesdy CP, Kalantar-Zadeh K]
通讯作者: Kalantar-Zadeh K
DOI: 10.1111/sdi.12706
发表时间: 2018-07
期刊: Seminars in dialysis
影响因子: 1.6
作者: [Moradi H, Streja E, Vaziri ND]
通讯作者: Vaziri ND
共 13 条
    HDL function and mortality in end stage renal disease
    • 批准号:
      9237202
    • 项目类别:
    • 资助金额:
      $0.0万
    • 财政年份:
      2015
    • 负责人:
      Hamid Moradi
    • 依托单位:
    Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
    Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
    • 批准号:
      7673186
    • 项目类别:
    • 资助金额:
      $6.1万
    • 财政年份:
      2009
    • 负责人:
      Hamid Moradi
    • 依托单位:
    Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
    国内基金
    海外基金
    补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
    芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
    • 批准号:
      82505677
    • 项目类别:
      青年科学基金项目(C类)
    • 资助金额:
      30.00万元
    • 批准年份:
      2025
    • 负责人:
      吕雨霏
    • 依托单位:
    麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
    • 批准号:
      82574874
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2025
    • 负责人:
      刘天华
    • 依托单位:
    靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
    • 批准号:
      JCZRQN202500010
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
    • 依托单位: